High Science 2010: Rising To The Challenge Of Driving Medtech Innovation In Turbulent Times
Medtech R&D productivity is being undermined by a range of deep-seated changes in the health care industry. Companies that underestimate this challenge face the prospect of lackluster growth over the long term. But in sharp contrast, Boston Consulting Group has identified a set of "High Science" device companies that are making a concerted effort to reinvent their approach to R&D and gain a competitive edge.
You may also be interested in...
While all of the attention is focused on US health care reform and how it may hurt medical technology, China is undertaking massive reform of its own, which looks to be a boon, first for equipment and diagnostics, then for devices.
The Boston Consulting Group reveals results of a study on how medical technology firms can cultivate and manage their R&D to boost revenue, profits, and even and stock valuations.
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.